<DOC>
	<DOC>NCT00923715</DOC>
	<brief_summary>The purpose of this study is to determine whether exenatide and pramlintide will improve blood glucose control after meals when compared to insulin alone.</brief_summary>
	<brief_title>Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>1. Age of 12 to 21 years. 2. HbA1C less than 9% 3. Subjects must be on intensive insulin management 4. Cpeptide less than 0.3 ng/ml 5. Tanner stage greater than or equal to 3 6. Having T1DM for at least one year 7. T1DM defined by ADA criteria and having at least one of the following antibodies a. AntiGAD (glutamic acid decarboxylase) b. Antiislet cell 512 (ICA512) c. Antiinsulin 8. Willing to give consent. 1. Type 2 diabetes. 2. Having any other chronic condition except hypothyroidism stable on medications. 3. On chronic medications that may affect glucose excursions. 4. Anemia as defined as Hb less than 9 gm/dl. 5. Abnormal AST, ALT, amylase, lipase or creatinine (twice normal). 6. Unsupportive family environment as determined by clinicians and/or social workers. 7. Pregnant or lactating mothers</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Diabetes Mellitus, Type 1</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Pramlintide</keyword>
</DOC>